NYSE: PRGOPerrigo Co PLC Stock
$25.62+0.43 (+1.71%)
Updated Apr 29, 2025
PRGO Price
$25.62
Fair Value Price
N/A
Market Cap
$3.50B
52 Week Low
$23.14
52 Week High
$33.46
P/E
-20.5x
P/B
0.81x
P/S
0.81x
PEG
N/A
Dividend Yield
3.29%
Revenue
$4.37B
Earnings
-$171.80M
Gross Margin
35.3%
Operating Margin
2.2%
Profit Margin
-3.9%
Debt to Equity
1.23
Operating Cash Flow
$363M
Beta
0.59
Next Earnings
May 2, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PRGO Overview
Perrigo Company plc manufactures over-the-counter health and wellness solutions that address upper respiratory, pain and digestive health. It also offers sleep-aids, nutrition, vitamin, and mineral supplements, as well as healthy lifestyle, skincare, personal hygiene, and oral self-care products. The company offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. Perrigo was founded in 1887 and is headquartered in Dublin, Ireland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PRGO's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
PRGO
Ranked#10 of 58
Ranked#10 of 58
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.75 | A | |
| $32.49 | A | |
| $27.00 | A |
Be the first to know about important PRGO news, forecast changes, insider trades & much more!
PRGO News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PRGO scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PRGO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PRGO is good value based on its book value relative to its share price (0.81x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.09x)
P/B vs Industry Valuation
PRGO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more PRGO due diligence checks available for Premium users.
Valuation
PRGO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-20.5x
Industry
21.8x
Market
29.19x
PRGO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.81x
Industry
2.09x
PRGO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PRGO's financial health
Profit margin
Revenue
$1.1B
Net Income
-$44.5M
Profit Margin
-3.9%
PRGO's Earnings (EBIT) of $96.00M... subscribe to Premium to read more.
Interest Coverage Financials
PRGO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.6B
Liabilities
$5.3B
Debt to equity
1.23
PRGO's short-term assets ($2.48B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRGO's long-term liabilities ($4.28B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRGO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PRGO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$312.6M
Investing
-$37.1M
Financing
-$1.2B
PRGO's operating cash flow ($362.90M)... subscribe to Premium to read more.
Debt Coverage Financials
PRGO vs Pharmaceutical Stocks
Perrigo Co Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.